Found: 10
Select item for more details and to access through your institution.
High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2.
- Published in:
- European Journal of Immunology, 2021, v. 51, n. 6, p. 1412, doi. 10.1002/eji.202049072
- By:
- Publication type:
- Article
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.761250
- By:
- Publication type:
- Article
Facilitating genome navigation: survey sequencing and dense radiation-hybrid gene mapping.
- Published in:
- 2005
- By:
- Publication type:
- research
An integrated 4249 marker FISH/RH map of the canine genome.
- Published in:
- BMC Genomics, 2004, v. 5, p. 65, doi. 10.1186/1471-2164-5-65
- By:
- Publication type:
- Article
Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Quantitative and qualitative changes in anti‐Neu5Gc antibody response following rabbit anti‐thymocyte IgG induction in kidney allograft recipients.
- Published in:
- European Journal of Clinical Investigation, 2019, v. 49, n. 4, p. N.PAG, doi. 10.1111/eci.13069
- By:
- Publication type:
- Article
Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0156775
- By:
- Publication type:
- Article
Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.
- Published in:
- Xenotransplantation, 2015, v. 22, n. 2, p. 85, doi. 10.1111/xen.12142
- By:
- Publication type:
- Article
Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients.
- Published in:
- Transplant International, 2011, v. 24, n. 6, p. 536, doi. 10.1111/j.1432-2277.2011.01251.x
- By:
- Publication type:
- Article
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1330178
- By:
- Publication type:
- Article